

ASX ANNOUNCEMENT

RESULTS OF MEETING

SYDNEY, Friday, 10 October 2014: Cellmid Limited (ASX: CDY) (Company) hereby gives notice to the Australian Securities Exchange (ASX) that shareholders of the Company passed all resolutions considered at the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were given to ASX on 8 September 2014.

This notice is given in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution	Result	Proxy Votes			
		For	Against	Discretion	Abstain
Resolution 1 Adopt the Remuneration Report for year end 30 June 2014	Passed on a show of hands	114,842,659	2,370,488	2,713,000	25,209,000
Resolution 2 Re-election of Martin Rogers as Director	Passed on a show of hands	160,737,930	2,348,297	6,734,620	3,340,000
Resolution 3 Approval for raising up to \$5 million by the issuing of ordinary shares within three months of the date of approval	Passed on a show of hands	164,646,239	1,528,488	6,627,120	359,000
Resolution 4 Ratification of prior issue of ordinary shares under placement	Passed on a show of hands	145,190,739	1,086,488	6,734,620	449,000
Resolution 5 Ratification of prior issue of ordinary shares to RM Research	Passed on a show of hands	163,215,930	2,841,297	6,734,620	369,000


Resolution 6 Approval of the Employee Incentive Plan	Passed on a show of hands	111,396,865	4,769,662	6,134,620	22,834,000
--	---------------------------------	-------------	-----------	-----------	------------

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in immuno-oncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.